Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma  by Coco, Simona et al.
Copyright © 2015 by the International Association for the Study of Lung Cancer
e50 Copyright © 2015 by the International Association for the Study of Lung Cancer
Letters to the Editor Journal of Thoracic Oncology ®  •  Volume 10, Number 6, June 2015
mutations. In this letter, we would like to 
share our experience of a case with a non-
conservative double amino acid change 
that has not been described before. 
A 76-year-old never-smoker woman in 
good clinical conditions was referred 
to our Institution for a solid lesion in 
the left lung. Subsequent procedures, 
including positron emission tomog-
raphy scan and fibrobronchoscopy, 
revealed a lung adenocarcinoma, con-
firmed by TTF-1 and CK7 immuno-
histochemistry positivity, apparently 
limited to the left upper lobe; therefore, 
the patient underwent radical left upper 
lobectomy. The surgical report revealed 
metastases in mediastinal lymph nodes 
and in the parietal pleura; the final 
stadiation was pT2b (G2), pN2, and 
pM1a for pleural involvement (stage 
IV). Consequently, we considered the 
patient eligible for systemic treatment. 
Sanger sequencing analysis revealed 
four consecutive genetic variants (GAA 
> GTT and TTA > CCA) in the exon 
19 of EGFR, resulting in double amino 
acid substitution: E746V and L747P, 
respectively.
Despite limited and partially 
discordant literature data available 
on these variants,1–3 we considered 
the patient eligible for treatment 
with gefitinib (250 mg/day), started 
in October 2013. Baseline computed 
tomography scan showed pleural effu-
sion and sub-centimetric lesions in the 
lower left lobe; during treatment, no 
radiological response was observed 
(Fig. 1). In May 2014, progressive dis-
ease was defined because of increase 
of left pleural effusion and appear-
ance of new mediastinal and left axil-
lar lymphadenopathies and pulmonary 
lesions. As clinical conditions wors-
ened, further treatments were limited 
to best supportive care until death, 
occurred in October 2014.
The poor outcome of the patient 
encouraged further investigations of 
this case: next generation sequencing 
did not disclose additional mutations, 
confirming our previous data on EGFR 
(Fig. 2A), and analysis in normal DNA 
pointed out the somatic origin of the 
variants.
Sanger sequencing of cDNA 
reported the transcription of these 
four mutations in approximately 50% 
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of tumor cells (Fig. 2B), whereas pro-
tein analysis on tumor tissue revealed 
a marked phosphorylation of EGFR 
when compared with the correspondent 
normal tissue, confirming the activat-
ing role of this double amino acid sub-
stitution (Fig. 2C). Three-dimensional 
structure analysis of our mutated 
EGFR model revealed a rotation of 
approximately 32-degree of Helix A 
(K730-V745), mimicking the EGFR 
structure resulting from T790M-L858R 
mutations, which is characterized by a 
restored ATP affinity and gefitinib resis-
tance.4 This rotation determines a cleft 
allowing the protein to simultaneously 
bind one molecule of gefitinib and one 
molecule of ATP, in a favorable position 
to successfully undergo hydrolysis, as 
also demonstrated by our docking sim-
ulation (Fig. 3).
DISCUSSION
Here, we report the case of a patient 
affected by advanced lung adenocarci-
noma harboring four novel consecutive 
missense mutations in the exon 19 of 
the EGFR gene that result in noncon-
servative double amino acid change 
(E746V-L747P).
Although tyrosine kinase inhibi-
tors (TKIs) are generally recommended 
in EGFR-mutant lung adenocarcinoma, 
to date relatively little is known con-
cerning the EGFR activation status 
related to rare mutations and their sen-
sitivity to TKI.1–3,5
Our data confirmed the somatic 
origin of E746V-L747P genetic vari-
ants and their activating role on EGFR; 
structure prediction revealed a dra-
matic rearrangement of the N-terminal 
lobe of EGFR tyrosine kinase domain 
allowing ATP binding, irrespective of 
gefitinib. Indeed, docking simulations 
pointed out the high affinity of ATP to 
the double mutant in a position highly 
favorable for hydrolysis, resulting in 
TKI resistance.
The activating role of E746V-L747P 
mutations resulting in aberrant rearrange-
ment of the EGFR structure, strongly 
supported by our data, confers weak TKI 
sensitivity and treatment failure.
This case highlights the impor-
tance of EGFR uncommon mutations 
on protein structure as a putative pre-
dictor of TKI efficacy.
DOI: 10.1097/JTO.0000000000000538
Copyright © 2015 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/15/1006-0e50
To the Editor:
Recently, we read with interest 
the article by van der Wekken et al.1 
regarding the role of uncommon EGFR 
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FIGURE 1. A, Computed tomography (CT)-scan showing left lower pleural effusion at baseline, although no measureable 
lesions were reported. B, CT-scan during gefitinib treatment revealed a progressive increase of the sub-centimetric nodules and 
increase pleural effusion.
FIGURE 2. A, Next generation sequencing. Tumor DNA was sequenced by Ion PGM System (Life Technologies, Carlsbad, CA) using 
“Colon and Lung Cancer Research Panel” v.1. Integrative Genomics Viewer displays four consecutive heterozygous substitutions 
in the exon 19 of the EGFR (55242467, 55242468, 55242469, and 55242470). These genetic variants lead to double amino acid 
substitution E746V-L747P. B, Sanger sequencing of EGFR transcript. Total RNA from normal surrounding lung tissue (N) and adenocar-
cinoma (T) snap frozen samples were retrotranscribed and bidirectional sequencing using F:5′-TTGTGGAGCCTCTTACACCC-3′ and 
R:5′-TGTCTTTGTGTTCCCGGACA-3′ by ABI-Prism 3130 (Life Technologies). The electropherogram of T shows four consecutive mixed 
peaks compared with the N cDNA, confirming the mutations in approximately 50% of tumors cells. C, Western blot analysis of EGFR 
phosphorylation status. Upper panel: marked increase of EGFR phosphorylated form (EGFR-P) is observed in T compared with the 
matched N, confirming EGFR activation in exon 19 E746V-L747P sample. Lower panel: EGFR-P in T samples from three non–small-
cell lung cancer tumors with a distinct EGFR mutational status: EGFR wild type (EGFR WT); exon 19 E746V-L747P (EGFR MUT), and 
exon19 delE746-A750 (EGFR DEL). Notably, exon 19 E746V-L747P tumor shows high EGFR-P.
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FIGURE 3.  Predicted protein structure of the 
double mutant E746V-L747P. This structural rear-
rangement allows ATP (orange and blue chemi-
cal structure) binding, even in the presence of 
gefitinib (purple chemical structure), in a favor-
able position for hydrolysis. Visual analysis of the 
protein structures based on native EGFR alone, in 
complex either with tyrosine kinase inhibitor or 
ATP analogue, mutated EGFR with gefitinib from 
Protein Data Bank (http://www.rcsb.org/pdb/
home/home.do. Accessed February 10, 2015; 
PDB: 4WRG, 4WKQ, 4HJO, 4G5J, 4I23, 3VJO, 
4I22), was carried over using the program COOT 
and figure was drawn using the program Chimera.
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To the Editor:
The recent report on “MicroRNA 
Assays to Distinguish Squamous Cell 
Carcinoma from Adenocarcinoma in 
Lung Cancer Biopsies” is very interest-
ing.1 Patnaik et al.1 noted that “histotypic 
microRNA assays can aid the subtyping 
of non-small-cell lung cancer biopsies as 
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